Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-strong trading volume on Monday . Approximately 28,678 shares were traded during mid-day trading, an increase of 12% from the previous session’s volume of 25,561 shares.The stock last traded at $6.02 and had previously closed at $6.05.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IVA shares. Guggenheim raised their target price on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. HC Wainwright started coverage on Inventiva in a report on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Piper Sandler started coverage on Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Inventiva Stock Down 1.7%

The stock has a fifty day moving average of $4.61 and a 200-day moving average of $3.75.

Institutional Trading of Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC lifted its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 at the end of the most recent reporting period. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.